Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 214

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 214
---
 of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.

As of September 30, 2025 and December 31, 2024, there was no outstanding debt under the Credit Line. 

10.    Share-Based Payments

Share-based compensation expense is as follows (dollars in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Research and development$1,446 $1,350 $4,337 $3,946 Selling, general and administrative(1)29,299 6,324 41,983 16,177 Total$30,745 $7,674 $46,320 $20,123 (1) Includes $22.9 million of compensation expense related to the acceleration of certain Sage equity awards in connection with the Sage Acquisition in July 2025. The Company has $14.4 million of unrecognized compensation expense related to CVRs granted to holders of the accelerated Sage equity awards. This unrecognized compensation expense will be recognized if and when the milestones associated with the CVRs become probable of achievement.Stock Option The following table summarizes stock option activities:Number ofOptionsWeighted AverageExercise PriceWeightedAverageRemainingContractualTerm (in years)Outstanding, December 31, 20246,719,073 $30.44 5.9Granted 1,101,645 $33.82 Exercised (1,171,953)$23.71 Forfeited (128,117)$33.88 Outstanding, September 30, 2025 (unaudited)6,520,648 $32.15 6.3As of September 30, 2025 (unaudited):Vested and expected to vest6,520,648 $32.15 6.3Exercisable 3,857,789 $31.76 4.8As of December 31, 2024:Vested and expected to vest6,719,073 $30.44 5.9Exercisable4,137,283 $29.54 4.4Restricted Stock UnitsThe following table summarizes restricted stock unit (RSU) activities:Number ofRSUsWeighted AverageGrant Date Fair Value per ShareNonvested, December 31, 2024378,165 $32.